Mangrove Therapeutics
Sacramento, US · Founded 2025 · Delaware corporation
Founders & leadership
BZ
Benjamin Zhiyi ChenChief Executive Officer (Interim) / President
AS
Alexander Simon GreenChief Financial Officer
Treasurer
JL
Jin LiNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2026
▶$2.5MraisedJul 2026 · 9 investors · BiotechnologyRule 506(b)
▶$2.5MraisedJul 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jin LiDirector
- Benjamin Zhiyi ChenExecutive Officer, Director
- Alexander Simon GreenExecutive Officer
- Offering amount
- $5M
- Amount sold
- $2.5M
- Minimum investment
- $25K
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Mangrove Therapeutics raised?
- Mangrove Therapeutics has disclosed $2.5M raised across 1 round.
- Where is Mangrove Therapeutics headquartered?
- Mangrove Therapeutics is headquartered in Sacramento, US.